LivaNova PLC Form 8-K Summary
Business Context and Reporting Period
LivaNova PLC, a medical technology company incorporated in England and Wales, filed this Current Report on Form 8-K on March 29, 2019, regarding events occurring on March 26, 2019. The filing details the entry into a new material definitive agreement to secure financing for general corporate purposes.
Key Financial Metrics and Debt Structure
The company established a new multicurrency term loan facility with an aggregate principal amount of $350 million. The filing does not provide current revenue, profit, cash flow, or margin data, as this is a transactional report rather than a periodic financial statement.
- Total Facility Amount: $350 million
- Tranche Composition:
- U.S. Dollar Tranche: $233,333,333
- Euro Tranche: EUR 103,016,924.50 (equivalent to $116,666,667 at a fixed rate of 1.1325)
- Interest Rates: LIBOR + 1.60% (USD) or EURIBOR + 1.40% (EUR)
- Termination Date: March 26, 2022
- Use of Proceeds: General corporate and working capital purposes (explicitly excluding acquisitions, dividends, and share buybacks)
Material Changes and Financial Covenants
This facility replaces a previous US$70 million revolving facility from Barclays Bank PLC, which was required to be cancelled and repaid in full prior to the first utilization of the new loan. The agreement imposes strict financial covenants that LivaNova must maintain:
- Net Debt to EBITDA: Maximum consolidated ratio tested semi-annually.
- Interest Coverage: Minimum ratio tested on June 30 (6-month period) and December 31 (12-month period).
- Net Debt to Net Worth: Maximum consolidated ratio tested semi-annually.
- Net Worth: Minimum consolidated amount required at all times.
Outlook, Risks, and Contingencies
The agreement includes significant restrictions and events of default that could impact the company's financial flexibility and operations.
- Restrictions: Limits on incurring additional indebtedness, granting security over assets, or providing loans to subsidiaries.
- Change of Control: Lenders may require prepayment if LivaNova loses control of Sorin Group Italia srl or undergoes a change of control.
- Events of Default: Include failure to meet covenants, non-payment, insolvency, material misrepresentation, or a "Material Adverse Effect" on the business. Specifically, if auditors qualify the financial statements due to inadequate information or inability to prepare accounts on a going concern basis, it constitutes an event of default.
- Legal Jurisdiction: The agreement is governed by English law.
Investor Verification Checklist
- Verify the full text of the Facility Agreement (Exhibit 10.1) for specific definitions of "Net Debt" and "EBITDA" used in covenants.
- Confirm the status of the repayment of the previous US$70 million Barclays revolving facility.
- Monitor upcoming semi-annual and annual financial reports to ensure compliance with the new debt-to-EBITDA and interest coverage ratios.
- Assess the impact of the restriction on acquisitions and share buybacks on the company's strategic growth plans.
- Review the company's liquidity position to ensure it can service the variable interest rates and commitment fees associated with the undrawn portion of the facility.